0001104659-26-017575
SEC filingPTC Therapeutics, Inc. reported strong financial results for fiscal year 2025, achieving total revenues of $1.73 billion and net income attributable to common stockholders of $682.6 million. The company generated operating income of $866.9 million, driven by revenue growth and controlled operating expenses totaling $863.7 million. Key profitability drivers included a gain on sale of priority review voucher of $99.9 million, partially offset by interest expense of $152.2 million and loss on extinguishment of debt of $137.6 million. The company maintained a solid liquidity position with cash and cash equivalents of $984.6 million and marketable securities of $960.7 million, while total assets stood at $2.90 billion. Operating cash flow was strong at $711.2 million, though investing activities used $862.0 million primarily for marketable securities purchases and acquisitions. The company's balance sheet shows total liabilities of $3.10 billion and stockholders' deficit of $205.3 million, reflecting significant long-term obligations including liability for sale of future royalties of $2.31 billion.
PTC Therapeutics, Inc. delivered strong financial performance for fiscal year 2025, reporting total revenues of $1.73 billion and net income attributable to common stockholders of $682.6 million. The company achieved operating income of $866.9 million, representing an operating margin of 50.1%. Key components of operating expenses included research and development costs of $455.2 million, selling, general and administrative expenses of $347.1 million, and cost of product, collaboration and license sales of $47.0 million. The company also recorded intangible asset impairment of $159.5 million and tangible asset impairment of $9.6 million. Non-operating items included interest expense of $152.2 million, gain on sale of priority review voucher of $99.9 million, and loss on extinguishment of debt of $137.6 million, resulting in income before income tax of $696.6 million.
The company reported total revenues of $1.73 billion for fiscal year 2025. The document does not provide segment breakdown, geographic mix, or specific revenue growth drivers beyond the aggregate total revenue figure. No product-specific revenue figures are disclosed in the provided data, with all revenue line items showing as N/A except for the total revenues amount. The company's revenue composition and growth drivers are not detailed in the available information.
The company achieved strong profitability metrics with operating income of $866.9 million on total revenues of $1.73 billion, representing an operating margin of 50.1%. Gross profit can be calculated as $1.68 billion (total revenues of $1.73B minus cost of product, collaboration and license sales of $47.0M), resulting in a gross margin of approximately 97.3%. The cost structure shows significant investment in research and development at $455.2 million and selling, general and administrative expenses at $347.1 million. The company recorded substantial non-cash charges including intangible asset impairment of $159.5 million and amortization of acquired intangible assets of $24.7 million.
The company generated strong operating cash flow of $711.2 million for fiscal year 2025, driven by net income of $682.6 million adjusted for non-cash items including depreciation and amortization of $38.8 million, intangible asset impairment of $159.5 million, and share-based compensation of $74.5 million. Investing activities used $862.0 million primarily for purchases of marketable securities ($1.36B) and acquisition of product rights and licenses ($291.2M), partially offset by proceeds from sales. Financing activities provided $331.1 million mainly from exercise of options and employee stock purchases. The balance sheet shows total assets of $2.90 billion including cash and cash equivalents of $984.6 million and marketable securities of $960.7 million. Total liabilities of $3.10 billion include significant long-term obligations, resulting in stockholders' deficit of $205.3 million.
The provided document does not contain management guidance, strategic priorities, or specific risk factors that would typically be included in the outlook section of a 10-K filing. No forward-looking statements, future projections, or strategic initiatives are disclosed in the available financial data and document content. The analysis is limited to the historical financial results presented in the income statement, balance sheet, and cash flow statement for fiscal year 2025.